Free Trial
NASDAQ:ATXI

Avenue Therapeutics 8/10/2023 Earnings Report

Avenue Therapeutics logo
$0.26 +0.01 (+4.04%)
As of 05/28/2025 03:59 PM Eastern

Avenue Therapeutics EPS Results

Actual EPS
-$39.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Avenue Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Avenue Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Avenue Therapeutics' next earnings date is estimated for Thursday, August 7, 2025, based on past reporting schedules.

Conference Call Resources

Avenue Therapeutics Earnings Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
See More Avenue Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avenue Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avenue Therapeutics and other key companies, straight to your email.

About Avenue Therapeutics

Avenue Therapeutics (NASDAQ:ATXI), a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

View Avenue Therapeutics Profile

More Earnings Resources from MarketBeat